ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 0379 • ACR Convergence 2025

    Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study

    Rosa Maria Morlà Novell1, Enrique González-Dávila2, Beatriz Frade Sosa3, Maria López-Lasanta4, Noemí Busquets Pérez5, Marta Valls Roc6, Meritxell Sallés Lizarzáburu7, Georgina Salvador Alarcón8, Virginia Ruiz-Esquide9, Lola Tobalina Mastre10, José Gomez-Puerta11 and Raimon Sanmartí9, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hospital Universitari Vall d´Hebron, Barcelona, Spain, 5Hospital de Granollers, Granollers, Spain, 6Hospital Universitari Dr Trueta, Girona, Sudan, 7Xarxa Sanitària Althaia Manresa, Manresa, Spain, 8Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 9Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 10IDIBAPS. Hospital Clinic de Barcelona, Barcelona, 11Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
  • Abstract Number: 0153 • ACR Convergence 2025

    Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER

    Isabel Castrejón Fernández1, Lucia Otero2, Antonio Mera-Valera3, Alicia Garcia4, Silvia Gomez-Sabater5, Raquel Martín-Domenech6, Jose Alvaro-Gracia7, Juan Camilo Sarmiento-Monroy8, Beatriz Ventosa2 and Fernando Sánchez-Alonso9, 1Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3H. Clínico Universitario de Santiago, Santiago de Compostela, 4Rheumatologist, La Laguna, Spain, 5Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, 6H. Universitario de Elda, Elda, Spain, 7Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, 8Hospital Clínic Barcelona, Barcelona, Spain, 9Sociedad Española de Reumatología, Madrid, Spain

    Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
  • Abstract Number: 2553 • ACR Convergence 2025

    Impact of Polypharmacy on Treatment Adherence and Its Effect on The Quality of Life in Patients with Rheumatic Diseases

    Egla Samantha Sanchez-Peralta1, Margarita Isabel Alarcon-Jarquin2, Vanessa L. Lopez-Flores2, Dionicio A. Galarza-Delgado3 and Diana E. Flores-Alvarado1, 1Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Treatment adherence is fundamental for adequate control of rheumatic diseases. Nevertheless, due to the chronic nature of these conditions, polypharmacy can impact treatment adherence,…
  • Abstract Number: 2098 • ACR Convergence 2025

    Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial

    Natalie Keller1, Bryant England2, Katherine Wysham3, Mercedes Quinones4, Marianna Olave5, Sarah Wetzel6, Hannah Brubeck7, Rachel Gillcrist6, Criswell Lavery8, Bibiana Ateh9, Bridget Kramer2, Kimberly Hayes6, Rui Xiao8, Kaitian Jin8, Alexis Ogdie8, Daniel K. White10, Tuhina Neogi11, Carla Scanzello12 and Joshua Baker8, 1University of Oklahoma, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Howard University Hospital and Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, 5Brown University, Philadelphia, PA, 6Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 7VA Puget Sound Health Care System, Seattle, WA, 8University of Pennsylvania, Philadelphia, PA, 9Washington VA Medical Center, Washington, District of Columbia, 10University of Delaware, Newark, DE, 11Boston University School of Medicine, Boston, MA, 12University of Pennsylvania, Philadelphia

    Background/Purpose: Intra-articular (IA) corticosteroid injections are commonly utilized for pain management in knee osteoarthritis (KOA). However, clinical characteristics associated with a greater benefit from corticosteroid…
  • Abstract Number: 1505 • ACR Convergence 2025

    Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada

    Romy Kallas1, Naiva Manuela Piatchou Donfack1, Deanna Jannat-Khah1, Cynthia Aranow2, Cristina Arriens3, Jill Buyon4, Megan Clowse5, Maria Dall'Era6, Richard Furie7, Ellen Ginzler8, Jennifer Grossman9, Kenneth Kalunian10, Diane Kamen11, Kichul Ko12, William McCune13, Brad Rovin14, Francisco Sanchez-Guerrero15, Saira Sheikh16, Kyriakos Kirou1 and Timothy Niewold17, 1Hospital for Special Surgery, New York, NY, 2Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4NYU Grossman School of Medicine, New York, NY, 5Duke University, Chapel Hill, NC, 6Division of Rheumatology, University of California, San Francisco, CA, 7Division of Rheumatology, Northwell Health, Great Neck, NY, 8SUNY Downstate Health Sciences University, New York, NY, 9UCLA, Sherman Oaks, CA, 10UC San Diego, La Jolla, CA, 11Medical University of South Carolina, Johns Island, SC, 12The University of Chicago, Chicago, IL, 13U Michigan, Ann Arbor, MI, 14The Ohio State University, Columbus, OH, 15University Health Network/Sinai Health system, Toronto, ON, Canada, 16University of North Carolina at Chapel Hill, Chapel Hill, NC, 17Hospital for Special Surgery, New York, New York

    Background/Purpose: Understanding the discordance between patient- and physician-reported disease assessment scores is essential for incorporating patient-reported outcomes into disease activity measures and identifying gaps between…
  • Abstract Number: 1262 • ACR Convergence 2025

    Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study

    Cristina Arriens1, Fredonna Carthen2, Alexandre Cammarata-Mouchtouris1, Judith James1, Joan Merrill3 and Motolani Ogunsanya4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
  • Abstract Number: 0816 • ACR Convergence 2025

    Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs

    Andreas Kerschbaumer1, Marlene Steiner2, William H. Robinson3, Josef Smolen4 and Daniel Aletaha5, 1Stanford University / Medical University of Vienna, Stanford, CA, 2Medical University of Vienna, Vienna, Wien, Austria, 3Stanford University, Palo Alto, CA, 4Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 5Medical University Vienna, Wien, Austria

    Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…
  • Abstract Number: 0378 • ACR Convergence 2025

    Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis

    Preeti Dhanasekaran1, Bryant Lim2, Qai Ven Yap2, Hafizah Ahmad3, Siew Hwa Chong3, Ginny Goh3, Manjari Lahiri4, Amelia Santosa4, Gim Gee Teng3, Peter Cheung4, Siriwan Lim1 and Margaret Ma4, 1National University of Singapore, Singapore, Singapore, 2National University of Singapore, Singapore, 3National University Hospital, Singapore, 4National University Hospital, Singapore, Singapore

    Background/Purpose: The COVID-19 pandemic accelerated telemedicine adoption, yet readiness and digital literacy vary widely across patient populations. Understanding these differences is crucial to designing equitable…
  • Abstract Number: 2539 • ACR Convergence 2025

    Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort

    Sebastian E Sattui1, Amy Mudano2, Yujie Su2, Sandeep Sodhi3, Fenglong Xie4, Iris Navarro-Millan5, Robyn Domsic6 and Jeffrey Curtis7, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 3Illumination Health, Hoover, AL, 4The University of Alabama at Birmingham, Birmingham, AL, 5Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, 6University of Pittsburgh, Pittsburgh, PA, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Worse health-related quality of life has been reported in individuals with polymyalgia rheumatica (PMR), yet the factors contributing to this burden – including the…
  • Abstract Number: 2076 • ACR Convergence 2025

    Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions

    Latika Gupta1, Taanya Talreja2 and Peter Kerkhof3, 1School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, 2KEM Hospital, Mumbai, Maharashtra, India, 3Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The intersection of nutrition and autoimmune myopathies represents a significant yet understudied domain in rheumatological care. We conducted a meticulous analysis of online myositis…
  • Abstract Number: 1460 • ACR Convergence 2025

    Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study

    Stefan Siebert1, Mohamed Sharaf2, Frank Behrens3, Proton Rahman4, mitsumasa kishimoto5, Enrique R. Soriano6, Emmanouil Rampakakis7, László Köleséri8, Karissa Lozenski9, Ruben Queiro10, Ennio Lubrano11 and Laure Gossec12, 1University of Glasgow, Glasgow, United Kingdom, 2Janssen - Johnson & Johnson, Dubai, United Arab Emirates, 3Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, 5Kyorin University School of Medicine, Tokyo, Japan, 6Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7JSS Medical Research, Montréal, QC, Canada, 8IQVIA, Budapest, Hungary, 9Johnson & Johnson, Horsham, PA, 10Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, 11Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, 12Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France

    Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
  • Abstract Number: 1259 • ACR Convergence 2025

    Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study

    Angelo Gaffo1, Bhavisha Desai2, Abiola Oladapo3, Nana Kragh4, Rebekah Zincavage5, Brad Padilla5 and Naomi Schlesinger6, 1Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, 2Sobi, Glastonbury, CT, 3Sobi INC, Waltham, MA, 4Sobi, Kongens Lyngby, Denmark, 5Stratevi, Boston, 6Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT

    Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
  • Abstract Number: 0725 • ACR Convergence 2025

    Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis

    Rennie Rhee1, Christine Yeung2, Darrin White3, Mary Gibson3, Jessica Nguyen4, Cristina Burroughs5, Jennifer Gordon6, Noam A. Cohen4, Jeffrey Morris4 and Peter Merkel1, 1University of Pennsylvania, Philadelphia, PA, 2Vasculitis Patient-Powered Research Network, Philadelphia, PA, 32. Patient Research Partner, Vasculitis Patient-Powered Research Network, Philadelphia, 4University of Pennsylvania, Philadelphia, 5University of South Florida, Tampa, FL, 6Vasculitis Foundation, Kansas City, MO

    Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found…
  • Abstract Number: 0377 • ACR Convergence 2025

    New efforts to incorporate patient-reported outcomes into clinical trials for lupus therapeutics

    Patti Katz1, Anca Askanase2, Nandan Baruah3, Wen-Hung Chen4, Nicole Cooper5, Anna Fisch3, Lili Garrard6, Meenakshi Jolly7, Veronica Vargas Lupo8, Carla Menezes9, Judith Mills3, Hoang Nguyen10, Teodora Staeva5, Josephine Park11 and Zahi Touma12, 1UCSF, San Rafael, CA, 2Columbia University Medical Center, New York, NY, 3Lupus Voices Council, Lupus Accelerating Breakthroughs Consortium, New York, 4GlaxoSmithKline, Philadelphia, PA, 5Lupus Research Alliance, New York, 6FDA, CDER, SIlver Spring, MD, 7Rush University, Chicago, 8Lupus Voices Council, Lupus Research Alliance, New York, NY, 9Lupus Therapeutics, New York, NY, 10Lupus Research Alliance, New York, NY, 11EMDSerono, Boston, MA, 12University of Toronto, Toronto, ON, Canada

    Background/Purpose: Lupus Accelerating Breakthroughs Consortium (Lupus ABC) was formed by the Lupus Research Alliance as a public private partnership of people living with lupus, investigators,…
  • Abstract Number: 2508 • ACR Convergence 2025

    Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort

    Colebrooke Johnson1, Nora Shepherd2, David O'Dea1, Andrew King2, Guy Katz1, Belen Arevalo Molina1, Zachary Williams3, Madison Negron4, Naomi Patel1 and Sebastian H Unizony5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Nancy, KY, 4Harvard Extension School, Medford, MA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) imposes a high morbidity burden, both from the disease itself and from treatment-related side effects, often compromising patients’ quality of life…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 50
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology